pep2-SVKEInactive control peptide for pep2-SVKI CAS# 1315378-76-7 |
2D Structure
- CGS 21680
Catalog No.:BCC1475
CAS No.:120225-54-9
- CGS 21680 HCl
Catalog No.:BCC4316
CAS No.:124431-80-7
- Valsartan
Catalog No.:BCC5017
CAS No.:137862-53-4
- Istradefylline (KW-6002)
Catalog No.:BCC3798
CAS No.:155270-99-8
- Ticlopidine HCl
Catalog No.:BCC4973
CAS No.:53885-35-1
- Tozadenant
Catalog No.:BCC2011
CAS No.:870070-55-6
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 1315378-76-7 | SDF | Download SDF |
PubChem ID | 90479808 | Appearance | Powder |
Formula | C59H89N13O20 | M.Wt | 1300.43 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 1 mg/ml in 67% acetic acid | ||
Sequence | YNVYGIESVKE | ||
Chemical Name | (2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-oxobutanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]pentanedioic acid | ||
SMILES | CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)O)C(=O)O)NC(=O)CNC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(C(C)C)NC(=O)C(CC(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)N | ||
Standard InChIKey | AHURAWWDQDDHNP-OIKDQGPWSA-N | ||
Standard InChI | InChI=1S/C59H89N13O20/c1-7-31(6)49(58(90)65-38(19-21-45(78)79)53(85)69-42(28-73)55(87)72-47(29(2)3)56(88)64-37(10-8-9-23-60)52(84)66-39(59(91)92)20-22-46(80)81)70-44(77)27-63-51(83)40(25-33-13-17-35(75)18-14-33)68-57(89)48(30(4)5)71-54(86)41(26-43(62)76)67-50(82)36(61)24-32-11-15-34(74)16-12-32/h11-18,29-31,36-42,47-49,73-75H,7-10,19-28,60-61H2,1-6H3,(H2,62,76)(H,63,83)(H,64,88)(H,65,90)(H,66,84)(H,67,82)(H,68,89)(H,69,85)(H,70,77)(H,71,86)(H,72,87)(H,78,79)(H,80,81)(H,91,92)/t31-,36-,37-,38-,39-,40-,41-,42-,47-,48-,49-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Inactive control peptide analog of pep2-SVKI, an inhibitor peptide corresponding to last 10 amino acids of the C-terminus of the GluR2 AMPA receptor subunit. |
pep2-SVKE Dilution Calculator
pep2-SVKE Molarity Calculator
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- MNI caged kainic acid
Catalog No.:BCC7297
CAS No.:1315378-75-6
- Bax inhibitor peptide, negative control
Catalog No.:BCC2395
CAS No.:1315378-74-5
- PDZ1 Domain inhibitor peptide
Catalog No.:BCC5883
CAS No.:1315378-73-4
- Scrambled 10Panx
Catalog No.:BCC1246
CAS No.:1315378-72-3
- TCS 184
Catalog No.:BCC5899
CAS No.:1315378-71-2
- pep2-AVKI
Catalog No.:BCC5787
CAS No.:1315378-69-8
- pep2-EVKI
Catalog No.:BCC5786
CAS No.:1315378-67-6
- NG25
Catalog No.:BCC1799
CAS No.:1315355-93-1
- B-Raf inhibitor
Catalog No.:BCC1437
CAS No.:1315330-11-0
- HG6-64-1
Catalog No.:BCC5459
CAS No.:1315329-43-1
- TMP269
Catalog No.:BCC3993
CAS No.:1314890-29-3
- Amyloid Beta-Peptide (1-40) (human)
Catalog No.:BCC1045
CAS No.:131438-79-4
- Rac1 Inhibitor F56, control peptide
Catalog No.:BCC5887
CAS No.:1315378-77-8
- NPEC-caged-(1S,3R)-ACPD
Catalog No.:BCC7653
CAS No.:1315379-60-2
- VU 591 hydrochloride
Catalog No.:BCC6126
CAS No.:1315380-70-1
- Triumbelletin
Catalog No.:BCN6779
CAS No.:131559-54-1
- Camelliaside B
Catalog No.:BCN3872
CAS No.:131573-90-5
- Calystegine A3
Catalog No.:BCN1884
CAS No.:131580-36-4
- Betulinaldehyde
Catalog No.:BCN1249
CAS No.:13159-28-9
- Amyloid Beta-peptide (25-35) (human)
Catalog No.:BCC1027
CAS No.:131602-53-4
- (+)-Pteryxin
Catalog No.:BCN3470
CAS No.:13161-75-6
- Rocilinostat (ACY-1215)
Catalog No.:BCC2144
CAS No.:1316214-52-4
- ACY-241
Catalog No.:BCC6460
CAS No.:1316215-12-9
- OPC 21268
Catalog No.:BCC7812
CAS No.:131631-89-5
Nicotinic receptors modulate the function of presynaptic AMPA receptors on glutamatergic nerve terminals in the trigeminal caudal nucleus.[Pubmed:26277383]
Neurochem Int. 2015 Nov;90:166-72.
In this study, we demonstrate the existence on trigeminal caudal nucleus (TCN) glutamatergic terminals of alpha4beta2 nicotinic receptors (nAChRs) capable of enhancing the terminals' spontaneous release of [(3)H]d-aspartate ([(3)H]D-Asp). In rat TCN synaptosomes, spontaneous [(3)H]D-Asp release was increased by nicotine and the nicotinic receptor agonists (+/-)epibatidine and RJR2403. The increase was potentiated by the positive allosteric modulator of nAChRs LY2087101, inhibited by the nicotinic antagonists mecamylamine (MEC) and dihydro-beta-erythroidine hydrobromide (DHbetaE), and unaffected by alpha-bungarotoxin (alpha-BgTx) and methyllycaconitine (MLA). Evidence of functional interaction was observed between the alpha4beta2 nAChRs and cyclothiazide-sensitive, alfa-amino-3-hydroxy-5-methyl-4-isoxazolone propionate (AMPA) receptors co-localized on the TCN synaptosomes. Brief pre-exposure of synaptosomes to 30 muM nicotine or 10 muM RJR2403 abolished the AMPA (100 muM) -induced potentiation of [K(+)]e-evoked [(3)H]D-Asp release, an effect that seems to be caused by nicotine-induced increases in the internalization of AMPA receptors. Indeed, the effects of nicotine-pretreatment were not seen in synaptosomes containing pre-entrapped pep2-SVKI, a peptide known to compete for the binding of GluA2 subunit to scaffolding proteins involved in AMPA endocytosis, while entrapment of pep2-SVKE, an inactive peptide used as negative control, was inefficacious. These findings show that nicotine can negatively modulate the function of AMPA receptors present on glutamatergic nerve terminals in the rat TCN. Dynamic control of AMPA receptors by the nicotinic cholinergic system has been observed under other experimental conditions, and it can contribute to the control of synaptic plasticity such as long-term depression and potentiation. Nicotine's ability to reduce the functionality of presynaptic AMPA receptors could contribute to its analgesic effects by diminishing glutamatergic transmission from the primary afferent terminals that convey nociceptive input to TCN.
In vitro exposure to nicotine induces endocytosis of presynaptic AMPA receptors modulating dopamine release in rat nucleus accumbens nerve terminals.[Pubmed:22771975]
Neuropharmacology. 2012 Oct;63(5):916-26.
Here we provide functional and immunocytochemical evidence supporting the presence on Nucleus Accumbens (NAc) dopaminergic terminals of cyclothiazide-sensitive, alfa-amino-3-hydroxy-5-methyl-4-isoxazolone propionate (AMPA) receptors, which activation causes Ca(2)(+)-dependent [(3)H]dopamine ([(3)H]DA) exocytosis. These AMPA receptors cross-talk with co-localized nicotinic receptors (nAChRs), as suggested by the finding that in vitro short-term pre-exposure of synaptosomes to 30 muM nicotine caused a significant reduction of both the 30 muM nicotine and the 100 muM AMPA-evoked [(3)H]DA overflow. Entrapping pep2-SVKI, a peptide known to compete for the binding of GluA2 subunit to scaffolding proteins involved in AMPA receptor endocytosis, in NAC synaptosomes prevented the nicotine-induced reduction of AMPA-mediated [(3)H]DA exocytosis, while pep2-SVKE, used as negative control, was inefficacious. Immunocytochemical studies showed that a significant percentage of NAc terminals were dopaminergic and that most of these terminals also posses GluA2 receptor subunits. Western blot analysis of GluA2 immunoreactivity showed that presynaptic GluA2 proteins in NAc terminals were reduced in nicotine-pretreated synaptosomes when compared to the control. The nACh-AMPA receptor-receptor interaction was not limited to dopaminergic terminals since nicotine pre-exposure also affected the presynaptic AMPA receptors controlling hippocampal noradrenaline release, but not the presynaptic AMPA receptors controlling GABA and acetylcholine release. These observations could be relevant to the comprehension of the molecular mechanisms at the basis of nicotine rewarding.
Functional roles of protein interactions with AMPA and kainate receptors.[Pubmed:12941441]
Neurosci Res. 2003 Sep;47(1):3-15.
The glutamate receptor subtypes AMPA and kainate are involved in synaptic transmission and synaptic plasticity in the CNS. Recently there has been considerable interest in understanding the molecular regulation of these receptors by proteins that directly bind to AMPA and kainate receptor subunits. Amongst the first interaction partners to be discovered were NSF, ABP, GRIP and PICK1, which bind the AMPA receptor subunit GLUA2. We have studied the functional roles of the interactions of these proteins in regulating AMPA receptor-mediated synaptic transmission and synaptic plasticity in the hippocampus. We have also started to investigate the functions of PICK1 and GRIP on kainate receptor-mediated synaptic transmission in this region. In this article we reflect upon this work, which has led to some new ideas about how AMPA and kainate receptors are regulated at synapses.
Interaction of the AMPA receptor subunit GluR2/3 with PDZ domains regulates hippocampal long-term depression.[Pubmed:11573007]
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11725-30.
The interaction of PDZ domain-containing proteins with the C termini of alpha-amino-3-hydroxy-5-methylisoxazolepropionate (AMPA) receptors has been suggested to be important in the regulation of receptor targeting to excitatory synapses. Recent studies have shown that the rapid internalization of AMPA receptors at synapses may mediate, at least in part, the expression of long-term depression (LTD). We have previously shown that phosphorylation of Ser-880 on the AMPA receptor GluR2 subunit differentially regulated the interaction of GluR2 with the PDZ domain-containing proteins GRIP1 and PICK1. Here, we show that induction of LTD in hippocampal slices increases phosphorylation of Ser-880 within the GluR2 C-terminal PDZ ligand, suggesting that the modulation of GluR2 interaction with GRIP1 and PICK1 may regulate AMPA receptor internalization during LTD. Moreover, postsynaptic intracellular perfusion of GluR2 C-terminal peptides that disrupt GluR2 interaction with PICK1 inhibit the expression of hippocampal LTD. These results suggest that the interaction of GluR2 with PICK1 may play a regulatory role in the expression of LTD in the hippocampus.
PDZ proteins interacting with C-terminal GluR2/3 are involved in a PKC-dependent regulation of AMPA receptors at hippocampal synapses.[Pubmed:11163273]
Neuron. 2000 Dec;28(3):873-86.
We investigated the role of PDZ proteins (GRIP, ABP, and PICK1) interacting with the C-terminal GluR2 by infusing a ct-GluR2 peptide ("pep2-SVKI") into CA1 pyramidal neurons in hippocampal slices using whole-cell recordings. Pep2-SVKI, but not a control or PICK1 selective peptide, caused AMPAR-mediated EPSC amplitude to increase in approximately one-third of control neurons and in most neurons following the prior induction of LTD. Pep2-SVKI also blocked LTD; however, this occurred in all neurons. A PKC inhibitor prevented these effects of pep2-SVKI on synaptic transmission and LTD. We propose a model in which the maintenance of LTD involves the binding of AMPARs to PDZ proteins to prevent their reinsertion. We also present evidence that PKC regulates AMPAR reinsertion during dedepression.
AMPA receptor-PDZ interactions in facilitation of spinal sensory synapses.[Pubmed:10526335]
Nat Neurosci. 1999 Nov;2(11):972-7.
Silent synapses form between some primary sensory afferents and dorsal horn neurons in the spinal cord. Molecular mechanisms for activation or conversion of silent synapses to conducting synapses are unknown. Serotonin can trigger activation of silent synapses in dorsal horn neurons by recruiting AMPA receptors. AMPA-receptor subunits GluR2 and GluR3 interact via their cytoplasmic C termini with PDZ-domain-containing proteins such as GRIP (glutamate receptor interacting protein), but the functional significance of these interactions is unclear. Here we demonstrate that protein interactions involving the GluR2/3 C terminus are important for serotonin-induced activation of silent synapses in the spinal cord. Furthermore, PKC is a necessary and sufficient trigger for this activation. These results implicate AMPA receptor-PDZ interactions in mechanisms underlying sensory synaptic potentiation and provide insights into the pathogenesis of chronic pain.